Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche invests $142m in Shanghai for infectious disease research

This article was originally published in Scrip

Executive Summary

Roche is showing its confidence in treatments for infectious diseases in China through a substantial new investment - as much as CHF136 million ($142 million) – to build a new laboratory facility for its R&D Innovation Center in Shanghai.

You may also be interested in...



Merck KGAA Invests €260m In Production Value Chain in China

German group Merck has inaugurated a major new pharmaceutical plant and announced a further investment in China, where it sees opportunities in essential drugs amid rising demand as the country broadens its basic healthcare coverage and its population ages.

Chinese Appetite For Medtech Could Shrink In Face Of Uncertainty

The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.

China’s Big And Small Next-Gen Sequencing Players Ride The Precision Medicine Wave

China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.

Topics

UsernamePublicRestriction

Register

SC027003

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel